rAAVen Therapeutics

Meet rAAVen Therapeutics at #BIO2024! Connect in the BIO One-on-One Partnering system to learn more about rAAVen Therapeutics and our engineered AAV capsids.

#ASGCT2024 Always wonderful to have the opportunity to share our knowledge of oligodendrocytes, their critical role in white matter diseases and myelin-based conditions and our developing toolkit which includes novel AAV capsids that directly target these cells. Thank you rAAVen Therapeutics for participating and for our partnership.

#ASGCT2024 The rAAVen Therapeutics team had an exciting opportunity to showcase our latest findings on AAVs targeting oligodendrocytes at Myrtelle sponsored symposium. Many thanks to Myrtelle and Jordana Holovach for organizing. Overall, it was a fantastic conference filled with inspiring presentations and important breakthroughs. Looking forward to reconnecting with everyone in New Orleans 2025!

#ASGCT2024 The rAAVen Therapeutics team had an exciting opportunity to showcase our latest findings on AAVs targeting oligodendrocytes at Myrtelle sponsored symposium. Many thanks to Myrtelle and Jordana Holovach for organizing. Overall, it was a fantastic conference filled with inspiring presentations and important breakthroughs. Looking forward to reconnecting with everyone in New Orleans 2025!

Excited to share the news of our partnership with Prevail Therapeutics

rAAVen Therapeutics is excited to announce a new partnership with Prevail Therapeutics to develop novel adeno-associated virus (AAV) capsids for disorders of the nervous system. rAAVen Therapeutics specializes in targeted AAV capsid engineering, and will lead on capsid engineering, discovery, screening, cloning, and validation. Prevail will drive preclinical research and IND-enabling studies, overseeing all aspects of manufacturing, clinical development, and commercialization of new drug candidates. “We are very happy and excited to announce this partnership with Prevail Therapeutics. This is our second large collaboration with an American company, and it further strengthens our position as a key player in the development of novel AAV capsids. With this agreement, we continue to strive to improve the quality of life for patients with genetic disorders,” says Marcus Davidsson, Founder & Chief Operating Officer at rAAVen Therapeutics. To learn more about AAVs and gene therapy, visit our websites: www.raaven.se; https://lnkd.in/d67YhyCR

rAAVen Therapeutics is excited to announce a new partnership with Prevail Therapeutics to develop novel adeno-associated virus (AAV) capsids for disorders of the nervous system. rAAVen Therapeutics specializes in targeted AAV capsid engineering, and will lead on capsid engineering, discovery, screening, cloning, and validation. Prevail will drive preclinical research and IND-enabling studies, overseeing all aspects of manufacturing, clinical development, and commercialization of new drug candidates. “We are very happy and excited to announce this partnership with Prevail Therapeutics. This is our second large collaboration with an American company, and it further strengthens our position as a key player in the development of novel AAV capsids. With this agreement, we continue to strive to improve the quality of life for patients with genetic disorders,” says Marcus Davidsson, Founder & Chief Operating Officer at rAAVen Therapeutics. To learn more about AAVs and gene therapy, visit our websites: www.raaven.se; https://lnkd.in/d67YhyCR

Wrapping up this year’s BioEurope Spring in Barcelona after some days of networking, partnering meetings, making new connections and meeting up with old friends and colleagues. A big thank you to SmiLe Venture Hub for the continued support.